SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:16461654.
  • 2
    Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774780.
  • 3
    Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation and aggressive chemotherapy in children with AML in remission: A report from the Children's Cancer Group. Blood. 2001;97:5662.
  • 4
    Woods WG, Alonzo T, Lange B, Jeha S, Estey EH. Acute myeloid leukemia (AML) in adolescents and young adults (AYAs): A comparison of outcomes between patients treated on childhood or adult protocols. Blood. 2001;98:462a463a.
  • 5
    Razzouk BI, Estey E, Pounds S, et al. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006;106:24952502.
  • 6
    Woods WG, Kobrinsky N, Buckley J, et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: A Children's Cancer Group Pilot Study. J Clin Oncol. 1993;11:14481457.
  • 7
    Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood. 1996;87:49794989.
  • 8
    Lange BJ, Dinndorf P, Smith FO, et al. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. J Clin Oncol. 2004;22:150156.
  • 9
    Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 2008;111:10441053.
  • 10
    Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2012;118:761769.
  • 11
    Gibson BES, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19:21302138.
  • 12
    Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896903.
  • 13
    Moore JO, Dodge RK, Amrein PC, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood. 1997;89:780788.
  • 14
    Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005;105:34203427.
  • 15
    Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia < 60 years old: Final induction results of CALGB Study 9621. J Clin Oncol. 2004;22:42904301.
  • 16
    Kolitz JE, George SL, Marcucci G, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B Study 19808. Blood. 2010;116:14131421.
  • 17
    Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. Blood. 1996;88:28412851.
  • 18
    Petersdorf SH, Rankin C, Head DR, et al. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (SWOG-9500). Am J Hematol. 2007;82:10561062.
  • 19
    Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest Oncology Group Study S0106: an International Intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood. 2009;114:326a
  • 20
    Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:43254336.
  • 21
    Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
  • 22
    Gray RJ. Class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:11411154.
  • 23
    Bleyer A, Montello M, Budd T, Saxman S. National survival trends of young adults with sarcoma; lack of progress is associated with lack of clinical trial participation. Cancer. 2005;103:18911897.
  • 24
    Ferrari A, Dileo P, Casanova M, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer. 2003;98:571580.
  • 25
    Paulussen M, Ranft A, Dirksen U, Jürgens H. Ewing tumours: outcome in children, adolescents and adult patients. Eur J Cancer. 2007;5(suppl):209215.
  • 26
    Eichenauer DA, Bredenfeld H, Haverkamp H, et al. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin Study Group. J Clin Oncol. 2009;27:60796085.
  • 27
    Howell DL, Ward KC, Austin HD, Young JL, Woods WG. Access to pediatric cancer care by age, race, and diagnosis, and outcomes of cancer treatment in pediatric and adolescent patients in the State of Georgia. J Clin Oncol. 2007;25:46104615.
  • 28
    Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol. 1999;107:6979.
  • 29
    Rytting M, Ravandi F, Estey E, et al. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer. 2010;116:52725278.
  • 30
    Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27:504510.
  • 31
    Canner J, Alonzo TA, Franklin J, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer. 2013;doi:10.1002/cncr.28342.
  • 32
    Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality recent in patients with newly-diagnosed AML given “intense” induction regimens: a report from SWOG and MD Anderson (American Society of Hematology Annual Meeting Abstracts). Blood. 2012;120: Abstract 129.